Tourmaline Bio, Inc.
A late-stage biotechnology company developing medicines targeting immune-mediated diseases. Its product candidate, TOUR006, is being developed for the primary and secondary indications of thyroid eye disease (TED), also known as Graves' ophthalmopathy, and atherosclerotic cardiovascular disease (ASCVD), with potential additional indications. Delaware-based
Overview
Overview | |
|---|---|
Country | United States |
State | New York |
Employees | 58 |
Founded | 2021 |
Financials | |
|---|---|
Market Capitalization | 382.39M |
Revenue | |
Operating Income | -38.85M |
Operating Margin | |
Net Income | -32.94M |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 4313 / 5373 |
Sector : Healthcare | 658 / 1144 |
Industry : Biotechnology | 289 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 3184 / 5565 |
Sector : Healthcare | 480 / 1182 |
Industry : Biotechnology | 231 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 4103 / 5436 |
Sector : Healthcare | 606 / 1164 |
Industry : Biotechnology | 269 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 4344 / 5330 |
Sector : Healthcare | 762 / 1174 |
Industry : Biotechnology | 342 / 667 |